Alexandre Mebazaa

Professor, head of department

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Alexandre Mebazaa is the head of the department at APHP in France. His research focuses on critical care outcomes, particularly related to COVID-19, heart failure, and acute kidney injury. Recent articles authored by him explore topics such as the associations of biomarkers in critically ill patients and the effectiveness of treatment strategies in heart failure. He is dedicated to advancing understanding and improving therapies in the field of acute care medicine.

Articles (10)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (2)

Koji Takagi

UNITED STATES

View details

Joost P Schanstra

INSERM Délégation régionale Midi-Pyrenees Limousin

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alexandre Mebazaa

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study.

Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?

Publisher Correction to: A universal predictive and mechanistic urinary peptide signature in acute kidney injury.

Targeting the 'vulnerable' period - first 3-6 months after an acute heart failure admission - the light gets brighter.

Guideline-directed medical therapy improves not only left but also right heart function.

Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: <i>Post-hoc</i> analyses of the phase II adrenomedullin and outcome in septic shock 2 trial.

A universal predictive and mechanistic urinary peptide signature in acute kidney injury.

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.

Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.

The approach to informed consent in acute care research - Authors' reply.

Collaborators (2)

Koji Takagi

Joost P Schanstra

Make your next move.